The EMA’s human medicines advisory committee has recommended approval of Eli Lilly’s Baqsimi ... Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable ...

Glucagon is a recognised therapy for the ... which was approved in 2019 as a hypoglycaemia rescue therapy for diabetics. Eli Lilly's nasal spray Baqsimi was also approved in 2019 for a similar ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Nasal spray is being recalled over microbial failure. The U.S. Food and Drug Administration shared information about the recall affecting NeilMed Pharmaceuticals’ NasoGel Spray, last week. Here ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...

Patrik Jonsson is an executive vice president at Eli Lilly and president of Lilly Cardiometabolic ... Like Ozempic, the new pill is designed to mimic the glucagon-like peptide 1 hormone that ...

Eli Lilly expands its partnership with AdvanCell to advance targeted alpha therapies using Pb-212 technology for cancer treatment. Lilly inks a global licensing deal with OliX for OLX75016 ...

GIP and glucagon. That appears to have more potent effects on a person's appetite and satisfaction with food than other treatments. Tirzepatide, the active ingredient in Eli Lilly's weight loss ...